In addition to improving energy substrate utilization through ketogenesis, SGLT2 inhibitors may also increase energy substrate delivery, lower oxygen consumption, and reduce hypoxia-induced kidney damage (Figure 4). Here, SLC5A2 is linked to Nephropathy.